Abstract
The hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) is strictly essential for viral replication and it has been used as viral target for anti-HCV drug development. All small molecules which have been identified to be selective non-nucleoside inhibitors (NNI) of the HCV RdRp to date are reported.
Keywords: HCV, RNA dependent RNA polymerase (RdRp), non-nucleoside, inhibition, drug development, antiviral, NNI, small molecules
Mini-Reviews in Medicinal Chemistry
Title: The Exploding Field of the HCV Polymerase Non-Nucleoside Inhibitors: Summary of a First Generation Compounds
Volume: 8 Issue: 12
Author(s): Enzo Tramontano
Affiliation:
Keywords: HCV, RNA dependent RNA polymerase (RdRp), non-nucleoside, inhibition, drug development, antiviral, NNI, small molecules
Abstract: The hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) is strictly essential for viral replication and it has been used as viral target for anti-HCV drug development. All small molecules which have been identified to be selective non-nucleoside inhibitors (NNI) of the HCV RdRp to date are reported.
Export Options
About this article
Cite this article as:
Tramontano Enzo, The Exploding Field of the HCV Polymerase Non-Nucleoside Inhibitors: Summary of a First Generation Compounds, Mini-Reviews in Medicinal Chemistry 2008; 8 (12) . https://dx.doi.org/10.2174/138955708786141061
DOI https://dx.doi.org/10.2174/138955708786141061 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Mini-Reviews in Medicinal Chemistry Recent Progress in Delivery of Therapeutic and Imaging Agents Utilizing Organic-Inorganic Hybrid Nanoparticles
Current Drug Delivery Gene Expression Profiling in Rodent Models for Schizophrenia
Current Neuropharmacology Biomedical Applications of Gold Nanoparticles
Current Topics in Medicinal Chemistry ANN-QSAR Model for Virtual Screening of Androstenedione C-Skeleton Containing Phytomolecules and Analogues for Cytotoxic Activity Against Human Breast Cancer Cell Line MCF-7
Combinatorial Chemistry & High Throughput Screening Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Erythropoietic Porphyrias: Animal Models and Update in Gene-Based Therapies
Current Gene Therapy Editorial (Thematic Issue: Targeting Anti-Cancer Agents and Cancer Treatments)
Anti-Cancer Agents in Medicinal Chemistry Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets A Therapeutic Potential of Animal β-hairpin Antimicrobial Peptides
Current Medicinal Chemistry Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties
Current Molecular Medicine The Influence of Cox-2 and Bioactive Lipids on Hematological Cancers
Current Angiogenesis (Discontinued) Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues
Current Drug Targets Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Quantificational Methylation Analysis of APC and AXIN2 in HBV-related Hepatocellular Carcinoma
Current Cancer Therapy Reviews HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery